McKesson Corporation ( (MCK) ) has released its Q2 earnings. Here is a breakdown of the information McKesson Corporation presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
McKesson Corporation is a diversified healthcare services leader that partners with various stakeholders to improve health outcomes by providing insights, products, and services in the healthcare sector. In its fiscal 2026 second quarter earnings report, McKesson Corporation announced record-high quarterly revenues of $103.2 billion, marking a 10% increase from the previous year, and raised its full-year adjusted EPS guidance. The company reported significant growth in its North American Pharmaceutical and Oncology & Multispecialty segments, with adjusted earnings per diluted share rising by 39% to $9.86. McKesson’s strategic focus on oncology and multispecialty services, along with disciplined execution, has driven sustainable long-term growth. The company generated $2.4 billion in cash flow from operations and returned $1.6 billion to shareholders in the first half of the fiscal year. Looking ahead, McKesson remains confident in its ability to create value for stakeholders and has raised its fiscal 2026 adjusted EPS guidance to a range of $38.35 to $38.85, reflecting anticipated growth of 16% to 18% compared to the prior year.